BACKGROUND: To investigate the prognostic importance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Using a prospective design, 118 consecutive participants with histologically confirmed metastatic (inoperable) NSCLC and Eastern Cooperative Oncology group (ECOG) 0-3 completed a six-minute walk test to assess functional capacity and questionnaire that assessed self-reported exercise behavior. Cox proportional models were used to estimate the risk of all-cause mortality according to six-minute walk distance (6MWD) (<358.5m, 358.5-450 m, ≥450 m) and exercise behavior (MET-hrswk(-1)) categories with adjustment for important covariates. RESULTS: Median follow-up was 26.6 months; 77 deaths were reported during this period. Functional capacity was an independent predictor of survival (P(trend)=0.003) and added incremental prognostic value beyond that provided by PS plus other traditional markers of prognosis (P(trend)=0.025). Compared with patients achieving a 6MWD <358.5m, the adjusted hazard ratio (HR) for all-cause mortality was 0.61 (95% CI, 0.34-1.07) for a 6MWD of 358.5-450 m, and 0.48 (95% CI, 0.24-0.93) for a 6MWD >450 m. In unadjusted analysis, there was a borderline significant effect of exercise behavior on survival (p=0.052). Median survival was 12.89 months (95% CI, 9.11-21.05 months) for those reporting <9MET-hrswk(-1) compared with 25.63 months (95% CI, 11.28 to ∞ months) for those reporting ≥9MET-hrswk(-1). CONCLUSIONS: Functional capacity is a strong independent predictor of survival in advanced NSCLC that adds to the prediction of survival beyond traditional risk factors. This parameter may improve risk stratification and prognostication in NSCLC.
BACKGROUND: To investigate the prognostic importance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Using a prospective design, 118 consecutive participants with histologically confirmed metastatic (inoperable) NSCLC and Eastern Cooperative Oncology group (ECOG) 0-3 completed a six-minute walk test to assess functional capacity and questionnaire that assessed self-reported exercise behavior. Cox proportional models were used to estimate the risk of all-cause mortality according to six-minute walk distance (6MWD) (<358.5m, 358.5-450 m, ≥450 m) and exercise behavior (MET-hrswk(-1)) categories with adjustment for important covariates. RESULTS: Median follow-up was 26.6 months; 77 deaths were reported during this period. Functional capacity was an independent predictor of survival (P(trend)=0.003) and added incremental prognostic value beyond that provided by PS plus other traditional markers of prognosis (P(trend)=0.025). Compared with patients achieving a 6MWD <358.5m, the adjusted hazard ratio (HR) for all-cause mortality was 0.61 (95% CI, 0.34-1.07) for a 6MWD of 358.5-450 m, and 0.48 (95% CI, 0.24-0.93) for a 6MWD >450 m. In unadjusted analysis, there was a borderline significant effect of exercise behavior on survival (p=0.052). Median survival was 12.89 months (95% CI, 9.11-21.05 months) for those reporting <9MET-hrswk(-1) compared with 25.63 months (95% CI, 11.28 to ∞ months) for those reporting ≥9MET-hrswk(-1). CONCLUSIONS: Functional capacity is a strong independent predictor of survival in advanced NSCLC that adds to the prediction of survival beyond traditional risk factors. This parameter may improve risk stratification and prognostication in NSCLC.
Authors: Christopher J Lettieri; Steven D Nathan; Robert F Browning; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr Journal: Respir Med Date: 2006-03-20 Impact factor: 3.415
Authors: Morten Quist; Mikael Rørth; Seppo Langer; Lee W Jones; Jørgen H Laursen; Helle Pappot; Karl Bang Christensen; Lis Adamsen Journal: Lung Cancer Date: 2011-08-03 Impact factor: 5.705
Authors: Lee W Jones; Rachel-Rose Cohen; Stephanie K Mabe; Miranda J West; Annick Desjardins; James J Vredenburgh; Allan H Friedman; David A Reardon; Emily Waner; Henry S Friedman Journal: J Neurooncol Date: 2009-02-11 Impact factor: 4.130
Authors: Lee W Jones; Carolyn J Peddle; Neil D Eves; Mark J Haykowsky; Kerry S Courneya; John R Mackey; Anil A Joy; Vikaash Kumar; Timothy W Winton; Tony Reiman Journal: Cancer Date: 2007-08-01 Impact factor: 6.860
Authors: M D Goncalves; S Taylor; D F Halpenny; E Schwitzer; S Gandelman; J Jackson; A Lukose; A J Plodkowski; K S Tan; M Dunphy; L W Jones; R J Downey Journal: Clin Radiol Date: 2018-01-06 Impact factor: 2.350
Authors: Vesile Yildiz Kabak; Patrick Calders; Tulin Duger; Jibril Mohammed; Eric van Breda Journal: Support Care Cancer Date: 2018-09-25 Impact factor: 3.603
Authors: Laurie E Steffen; Kevin E Vowles; Bruce W Smith; Gregory N Gan; Martin J Edelman Journal: Health Psychol Date: 2017-11-27 Impact factor: 4.267
Authors: C R Kelsey; J M Scott; A Lane; E Schwitzer; M J West; S Thomas; J E Herndon; M G Michalski; M E Horwitz; T Hennig; L W Jones Journal: Bone Marrow Transplant Date: 2014-07-28 Impact factor: 5.483
Authors: S Casla; P Hojman; I Márquez-Rodas; S López-Tarruella; Y Jerez; R Barakat; M Martín Journal: Clin Transl Oncol Date: 2014-06-04 Impact factor: 3.405
Authors: Antonia V Bennett; Bryce B Reeve; Ethan M Basch; Sandra A Mitchell; Mathew Meeneghan; Claudio L Battaglini; Abbie E Smith-Ryan; Brett Phillips; Thomas C Shea; William A Wood Journal: Qual Life Res Date: 2015-11-17 Impact factor: 4.147
Authors: Amy J Hoffman; Ruth Ann Brintnall; Barbara A Given; Alexander von Eye; Lee W Jones; Jean K Brown Journal: Cancer Nurs Date: 2017 Jan/Feb Impact factor: 2.592